Source-grounded facts extracted from First Tracks Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
First Tracks Biotherapeutics, Inc. entered into Sublease with AnaptysBio, Inc. (effective 2026-06-15).
“On June 15, 2026, First Tracks Biotherapeutics, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with AnaptysBio, Inc., a Delaware corporation (“AnaptysBio”), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”).”
First Tracks Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $50.5 million for the three months ended March 31, 2026.
“On May 14, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.”
First Tracks Biotherapeutics, Inc. issued 29,100,802 shares of Common Stock of common stock to AnaptysBio.
“the Company issued 29,100,802 shares of Common Stock to AnaptysBio in consideration for the transfer of certain entities that are part of AnaptysBio's biopharma business.”
First Tracks Biotherapeutics, Inc.: Bylaws became effective in connection with the Spin-Off.
“Our Bylaws (the “Bylaws”) also became effective in connection with the Spin-Off.”
First Tracks Biotherapeutics, Inc.: Amended and Restated Certificate of Incorporation became effective in connection with the Spin-Off.
“We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.”
First Tracks Biotherapeutics, Inc. entered into Transition Services Agreement with AnaptysBio.
“the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio”
First Tracks Biotherapeutics, Inc. entered into Separation and Distribution Agreement with AnaptysBio.
“the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio”
First Tracks Biotherapeutics, Inc. completed a disposition involving AnaptysBio, Inc. (closed 2026-04-20).
“On the Distribution Date, AnaptysBio completed the Spin-Off.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.